Lactobacillus acidophilus CRL 1014 improved “gut health” in the SHIME® reactor

BMC Gastroenterology

Elizeu A Rossi¹  Susana M Isay Saad³  Isabel Kimiko Sakamoto²  Maria A Tallarico Adorno²  Martha L Villarreal Morales³  Katia Sivieri¹ 

[1] Department of Food & Nutrition, Faculty of Pharmaceutical Sciences, São Paulo State University, Araraquara Jau Highway, Km1, Araraquara, SP, Brazil;Department of Hydraulic and Sanitation, University of São Paulo, São Carlos, SP, Brazil;University of São Paulo, Faculty of Pharmaceutical Sciences, 580, Prof. Lineu Prestes Av, São Paulo, SP 05508-000, Brazil

关键词: Gastrointestinal resource management;    Lactic acid bacteria;    Probiotics;    Gut microbiota;   

Others  :  857902
DOI  :  10.1186/1471-230X-13-100

 received in 2012-08-16, accepted in 2013-06-07,  发布年份 2013

【 摘 要 】

Background

How to maintain “gut health” is a goal for scientists throughout the world. Therefore, microbiota management models for testing probiotics, prebiotics, and synbiotics have been developed.

Methods

The SHIME^® model was used to study the effect of Lactobacillus acidophilus 1014 on the fermentation pattern of the colon microbiota. Initially, an inoculum prepared from human feces was introduced into the reactor vessels and stabilized over 2-wk using a culture medium. This stabilization period was followed by a 2-wk control period during which the microbiota was monitored. The microbiota was then subjected to a 4-wk treatment period by adding 5 mL of sterile peptone water with L. acidophilus CRL1014 at the concentration of 10⁸ CFU/mL to vessel one (the stomach compartment). Plate counts, Denaturing Gradient Gel Electrophoresis (DGGE), short-chain fatty acid (SCFA) and ammonium analyses were carried out for monitoring of the microbial community from the colon compartments.

Results

A significant increase (p < 0.01) in the Lactobacillus spp. and Bifidobacterium spp. populations was observed during the treatment period. The DGGE obtained showed changes in the lactobacilli community from the colon compartments of the SHIME^® reactor. The (SCFA) concentration increased (p < 0.01) during the treatment period, due mainly to significant increased levels of acetic, butyric, and propionic acids. However, ammonium concentrations decreased during the same period (p < 0.01).

Conclusions

This study showed the beneficial influence of L. acidophilus CRL 1014 on microbial metabolism and lactobacilli community composition for improving human health.

【 授权许可】

   
2013 Sivieri et al.; licensee BioMed Central Ltd.

【 图 表 】

【 参考文献 】

• [1]Bischoff SC: Gut health’: a new objective in medicine? BMC Med 2011, 9:3-14. BioMed Central Full Text
• [2]Rousseaux C, Thuru X, Gelot A, Barnich NC, Dubuquoy L, Merour E, Geboes K, Chamaillard M, Ouwehand LG, Carcano D, Colombel J, Ardid D, Desreumaux P: Lactobacillus acidophilus modulates intestinal pain and induces opioid and cannabinoid receptors. Nat Med 2007, 13:35-37.
• [3]Ouwehand A, Vesterlund S: Health aspects of probiotics. IDrugs 2003, 6:73-80.
• [4]Tiihonen K, Ouwehand AC, Rautonen N: Human intestinal microbiota and healthy agein. Ageing Res Rev 2010, 9:107-116.
• [5]Coudeyras S, Forestier C: Microbiote et probiotiques: impact en santé humaine. Canadian Journal of Microbiolgy 2010, 56:611-650.
• [6]Wallace TC, Guarner F, Madsen K, Cabana MD, Gibson G, Hentges E, Sanders ME: Human gut microbiota and its relationship to health and disease. Nutr Rev 2011, 69:392-407.
• [7]Vendrame S, Guglielmetti S, Riso P, Arioli S, Klimis-Zacas D, Porrini M: Six-week consumption of a wild blueberry powder drink increases bifidobacteria in the human Gut. J Agric Food Chem 2011, 59:1285-12820.
• [8]Smith S, Muir JG, Cameron-Smith D: Does the inclusion of moderate amounts of red meat in the diet of exercising older women impact on faecal markers of bowel health, including faecal lactoferrin? In NZNS & NSA. Kent Town, S. Aust: Joint New Zealand Nutrition Society and Nutrition Society of Australia Annual Scientific Meeting, Nutrition Society of Australia; 2007.
• [9]Collado MC, Donat E, Ribes-Koninckx C, Calabuig M, Sanz Y: Imbalances in faecal and duodenal Bifidobacterium species composition in active and non-active coeliac disease. BMC Microbiol 2008, 8:1-9. BioMed Central Full Text
• [10]Ortner M, Weber J, Hoffmann U, Schreiber S, Dietel M, Lochs H: Mucosal flora in inflammatory bowel disease. Gastroenterology 2002, 122:44-54.
• [11]Kim Y, Kim SH, Whang KY, Kim YJ, Oh S: Inhibition of Escherichia coli O157:H7 attachment by interactions between lactic acid bacteria and intestinal epithelial cells. J Microbiol Biotechnol 2008, 18:1278-1285.
• [12]Ukena SN, Singh A, Dringenberg U, Engelhardt R, Seidler U, Hansen W, Bleich A, Bruder D, Franzke A, Rogler G, Suerbaum S, Buer J, Gunzer F, Westendorf AM: Probiotic Escherichia coli Nissle 1917 inhibits leaky gutby enhancing mucosal integrity. PLoS One 2007, 2:e1308.
• [13]Wong JMW, Souza R, Kendall CWC, Emam A, Jenkins DJA: Colonic health: fermentation and short chain fatty acids. J Clin Gastroenterol 2006, 40:235-243.
• [14]Possemiers S, Verthé K, Uyttendaele S, Verstraete W: PCR-DGGE-based quantification of stability of the microbial community in a simulator of the human intestinal microbial ecosystem. FEMS Microbiol Ecol 2004, 49:495-507.
• [15]Van De Wiele T, Boon N, Possemiers S, Jacobs H, Verstraete : Prebiotic effect of chicory inulin in the simulator of the human intestinal microbial ecosystem. FEMS Microbiol Ecol 2004, 51:143-153.
• [16]De Boever P, Deplancke B, Verstraete W: Fermentation by gut microbiota cultured in a simulator of the human intestinal microbial ecosystem is improved by supplementing a soygerm powder. J Nutr 2000, 130:2599-2606.
• [17]Sivieri K, Cano VS, Valentini SR, Rossi EA: Demonstration of the cellular viability and safety of Enterococcus faecium CRL 183 in long-term experiments. Le Lait 2007, 87:59-69.
• [18]Molly K, Woestyne MV, Verstraete W: Development of a 5-step multichamber reactor as a Simulation of the Human Intestinal Microbial Ecosystem. Appl Microbiol Biotechnol 1993, 39:254-258.
• [19]Molly K, Vandewoestyne M, Desmet I, Verstraete W: Validation of the simulator of the human intestinal microbial ecosystem (SHIME) reactor using microorganism associated activities. Microb Ecol Health Dis 1994, 7:191-200.
• [20]Munoa FJ, Pares R: Selective medium for isolation and enumeration of Bifidobacterium spp. Appl Environ Microbiol 1998, 54:1715-1718.
• [21]Marzotto M, Maffeis C, Paternoster T, Ferrrario R, Rizzotti L, Pellegrino M, Dellaglio F, Torriani S: Lactobacillus paracasei: A survives gastrointestinal passage and affects the fecal microbiota of healthy infants. Res Microbiol 2006, 157:857-866.
• [22]Van De Wiele T, Boon N, Possemiers S, Jacobs H, Verstraete W: Inulin-type fructans of longer degree of polymerization exert more pronounced in vitro prebiotic effects. J Appl Microbiol 2007, 102:452-460.
• [23]Bedani R: Influência do consumo de “iogurte” de soja fermentado com Enterococcus faecium CRL 183 na microbiota intestinal de animais e humanos. Araraquara, São Paulo, Brasil: M.Sc. Dissertation.Faculdade de Ciências Farmacêuticas, UNESP; 2008:140.
• [24]Heilig HGHJ, Zoetendal EG, Vaughan EE, Marteau P, Akkermans ADL, De Vos WM: Molecular diversity of Lactobacillus spp. and other lactic acid bacteria in the human intestine as determined by specific amplification of 16S ribosomal DNA. Appl. Environ. Microbiol 2002, 68:114-123.
• [25]Lane DJ: 16s/23s RNA sequencing. In Nucleic acid techniques in bacterial systematics. Edited by Stackebrandt E, Goodfellow M. Chichester, United Kingdom: John Wiley & Sons; 1991:115-175.
• [26]Felsk WR: Cloning 16s rna genes and utilization to bacterial communities. In Molecular microbial ecology manual, supplement 5. Edited by Akkermans ADL, Van Elsas JD, De Bruijn FJ. Dordrecht: Kluwer Academic Publishers; 2001:1-16. CHAPTER 3.3.3
• [27]Muyzer GE, De Waal C, Uitterlinden GA: Profiling of complex popμlations by denaturing gradient gel electrophoresis of polymerase chain reaction-amplified genes coding for 16s RNA. Appl Environ Microbiol 1993, 59:695-700.
• [28]Sanguinetti CJ, Dias Neto E, Simpson AJG: Rapid silver staining and recovery of PCR products separated on polyacrylamide gels. Biotechniques 1994, 17:915-919.
• [29]Gibson GR, Fuller R: Aspects of in vitro and in vivo research approaches directed toward identifying probiotics and prebiotics for human use. J Nutr 2000, 130:391-395.
• [30]Macfarlane GT, Macfarlane S: Models for intestinal fermentation: association between food components, delivery systems, biovailability and functional interactions in the gut. Curr Opin Biotechnol 2007, 18:156-162.
• [31]Montesi A, Garcia-Albiach R, Pozuelo MJ, Pintado C, Goni I, Rotger R: Molecular and microbiological analysis of caecal microbiota in rats fed with diets supplemented either with prebiotics and probiotics. Int J Food Microbiol 2005, 98:281-289.
• [32]Guarner F, Malagelada JR: Gut flora in health and disease. Lancet 2003, 361:512-519.
• [33]Sivieri K, Bianchi F, Adorno MAT, Rossi EA: Fermentation by gut microbiota cultured in a simulator of the human intestinal microbial ecosystem is improved by probiotic Enterococcus faecium CRL 183. Functional foods and health disease 2011, 10:389-401.
• [34]Possemiers S, Marzorati M, Verstraete W, Van de Wiele T: Bacteria and chocolate: a successful combination for probiotic delivery. Int J Food Microbiol 2010, 141:97-103.
• [35]Gaschott T, Steinhilber D, Milovic V, Stein J: Tributyrin, a stable and rapidly absorbed prodrug of butyric acid, enhances antiproliferative effects of dihydroxycholecalciferol in human colon cancer cells. J Nutr 2001, 131:1839-1843.
• [36]Saemann MD, Bohmig GA, Osterreicher CH, Burtscher H, Parolini O, Diajos C, Stockl J, Horl WH, Zlabinger GJ: Anti-inflammatory effects of sodium butyrate on humanmonocytes: potent inhibition of IL-12 and up-regulation of IL-10 production. FASEB 2000, 14:2380-2382.
• [37]Berggren AM, Nyman EM, Lundquist I, Björck IM: Influence of orally and rectally administered propionate on cholesterol and glucose metabolism in obese rats. Br J Nutr 1996, 76:287-294.
• [38]Cummings JH, Rombeau JL, Sakata T: Physiological and clinical aspects of short-chain fatty acids. Cambridge: Cambridge University Press; 1995.
• [39]Velázquez OC, Lederer HM, Rombeau JL: Butyrate and the colonocyte, implications for neoplasia. Dig Dis Sci 1996, 41:727-739.
• [40]Wong JMW, de Souza R, Kendall CWC, Emam A, Jenkins DJA: Colonic health: fermentation and short chain fatty acids. J Clin Gastroenterol 2006, 40:235-243.
• [41]Ooi LG, Liong MT: Cholesterol-lowering effects of probiotics and prebiotics: a review of in vivo and in vitro findings. Int J Mol Sci 2010, 11:2499-2522.
• [42]Gilliland SE, Nelson CR, Maxwell C: Assimilation of cholesterol by Lactobacillus acidophilus. Appl Environ Microbiol 1985, 49:377-381.
• [43]Rossi EA, Carlos IZ, PEI YC, Valdez GF: Development of a novel fermented soymilk product with potential probiotic properties. European Food Research and Technology 1999, 5:305-307.
• [44]St-Onge MP, Farnworth ER, Jones PJH: Consumption of fermented and nonfermented dairy products: effects on cholesterol concentrations and metabolism. Am J Clin Nutr 2000, 71:674-681.
• [45]Macfarlane GT, Macfarlane S: Human colonic microbiota: ecology, physiology and metabolic potential of intestinal bacteria. Scand J Gastroenterol 1997, 222:S3-S9.
• [46]Bedani R, Rossi EA: Microbiota intestinal e probióticos: implicações sobre o câncer de cólon. J Port Gastrenterol 2009, 15:19-28.
• [47]Jackson-Thompson J, Ahmed F, German RR, Lai SM, Friedman C: Descriptive epidemiology of colorectal cancer in the United States, 1998–2001. Cancer 2006, 107:1103-1111.